🟢 Citius Pharmaceuticals is trading 7.1% up today after accelerating LYMPHIR commercial adoption

Citius Pharmaceuticals is trading 7.1% up at $0.69 after Citius Oncology reported accelerating LYMPHIR commercial adoption.

• New ordering institutions rose 78% quarter over quarter to 42 sites, while vial orders increased 31% during the quarter ended June 30, 2026.
• Additional wholesaler reorders, near-universal payer coverage and expanding academic-center access further support the company’s commercialization outlook.
• The gain follows a 17.79% decline on August 6, 2026, and a 25.45% rise on August 5, 2026.